ArticleMolecular biology reports2023
Naringenin in combination with quercetin/fisetin shows synergistic anti-proliferative and migration reduction effects in breast cancer cell lines.
Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Liposomal and Micellar-Based Nanoformulations of Fluorinated Curcumin Derivative and Naringenin-Comparative Studies.Nanomaterials (Basel, Switzerland) · 2026Article
- Synergistic Induction of Caspase-8-Mediated Leukaemic Cell Death by Fisetin and Pinocembrin.International journal of molecular sciences · 2026Article
- Fisetin-loaded Nanoemulsion and Fecal Microbiome Extract Enhance In Vitro Inhibition of Non-Small Cell Lung Cancer Progression.Cell biochemistry and biophysics · 2026Article
- Effects of Naringenin in Preclinical Models of Breast Cancer.Biomolecules · 2026Review
- Evaluation of the anticancer effects of ellagic acid and cisplatin in cisplatin-sensitive and -resistant MDA-MB-231 breast cancer cells.Medical oncology (Northwood, London, England) · 2026Article
- Synergistic combinatorial anticancer potential of Tamoxifen with Naringin and Diosmetin in MCF-7 breast cancer cells and their liposomal delivery.Scientific reports · 2026Article
- Flavonoids and miRNA Modulation: A Novel Approach to Managing Cancer, Diabetes, Depression, and Neurological Disorders.BioMed research international · 2026Review
- ECSCR functions as a potential tumor suppressor in breast cancer cells.Medical oncology (Northwood, London, England) · 2025Article
- Investigating therapeutic potential of Evodiamine by identifying differentially expressed genes in cisplatin resistance non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2025Article
- Chrysin mitigates therapy-induced senescence in breast cancer via cGAS-STING pathway inhibition.Medical oncology (Northwood, London, England) · 2025Article
- Fisetin as a chemoprotective and chemotherapeutic agent: mechanistic insights and future directions in cancer therapy.Medical oncology (Northwood, London, England) · 2025Review
- An Updated Review Summarizing the Anticancer Potential of Naringenin.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Quercetin: A Natural Ally in Combating Breast Cancer.International journal of nanomedicine · 2025Review
- Effect of the polyphenol flavonoids fisetin and quercetin on the adipogenic differentiation of human mesenchymal stromal cells.Bioscience reports · 2024Article
- Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics.Frontiers in pharmacology · 2024Review
- Therapeutic Efficacy of Quercetin and Its Nanoformulation Both the Mono- or Combination Therapies in the Management of Cancer: An Update with Molecular Mechanisms.Journal of tropical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION &
aimBreast cancer is one of the most common cancers with a high mortality rate among women worldwide. Quercetin/fisetin and naringenin, three well-known flavonoids, have been used to fight against various cancers. The aim of the present study was to investigate the possible synergism of quercetin/fisetin with naringenin on MCF7 and MDA-MB-231 breast cancer cell lines.
methodsIn this study, cultured MCF7 and MDA-MB-231 cells were treated with different concentrations of quercetin/fisetin individually and in combination with naringenin. MTT assay and scratch assay was employed to determine cell viability and migration respectively. Real-time PCR was used to study the expression level of apoptosis genes and miR-1275 (tumor suppressor miRNA) and mir-27a-3p (oncogenic miRNA).
resultsA synergism effect of quercetin/fisetin and naringenin (CI < 1) was observed for both cell lines. Combination therapies were significantly more effective in cell growth reduction, migration suppression and apoptosis induction than single therapies. Gene expression analysis revealed the upregulation of miR-1275 and downregulation miR-27a-3p.
conclusionOur results indicate that quercetin/fisetin enhances the anti-proliferative and anti-migratory activities in combination with naringenin in MCF7 and MDA-MB-231 human breast cancer cell lines. Therefore, the combination of Que/Fis and Nar can be proposed as a promising therapeutic strategy for further investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.